Agenus
Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs
Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development
Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus
Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal
Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo
Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff
FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search
Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership